Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
394 stopped studies mapped to Hepatocellular Carcinoma and descendants · 93% state a reason
Over the 394 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Phase 2 | terminated | Dec 20, 2018 | Abramson Cancer Center at Penn Medicine | Safety letter from sponsor | Safety / toxicity |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion…(LIDA-ADJ) | Phase 2 | withdrawn | Nov 26, 2019 | University Hospital, Montpellier | no participants enrolled | Enrollment / accrual |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of… | Phase 2 | withdrawn | Apr 14, 2022 | OHSU Knight Cancer Institute | Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending… | Funding |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | N/A | terminated | Jul 22, 2010 | University Hospital Heidelberg | Slow recruitment rate | Enrollment / accrual |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced… | Phase 1 | terminated | Oct 26, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Loss of funding | Funding |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice… | Phase 3 | terminated | Aug 2, 2021 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk… | Phase 1 / Phase 2 | terminated | May 10, 2019 | Zhejiang University | The study has gotten preliminary results and stopped advanced. | Other (stated, no rule matched) |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | Phase 1 | terminated | Jun 25, 2019 | Eureka Therapeutics Inc. | Reallocation of resources to new HCC study. | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT04775056 | A Study to Evaluate Vaccines Against COVID-19 in the Real World | — | withdrawn | Mar 1, 2021 | Humanity & Health Medical Group Limited | No sponsor | Other (stated, no rule matched) |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | N/A | terminated | May 18, 2015 | Wright State University | Insufficient number of subjects meeting inclusion criteria | Other (stated, no rule matched) |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Oct 14, 2015 | Kathy Miller | Funder Decision | Other (stated, no rule matched) |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | Phase 2 | terminated | Sep 4, 2008 | BTG International Inc. | Study terminated prematurely by sponsor for business reason. One patient was enrolled. | Enrollment / accrual |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | N/A | terminated | Jan 18, 2018 | Duke University | Lack of enrollment | Enrollment / accrual |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Lion TCR Pte. Ltd. | Major changes in manufacturing process and investigational product | Drug supply |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC…(PATRON) | Phase 3 | terminated | Jul 26, 2011 | Cellxpert Biotechnology Corp. | Due to Interim Analysis and business concerns | Efficacy / futility |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | N/A | terminated | May 21, 2019 | Institut du Cancer de Montpellier - Val d'Aurelle | Change of the scientific and medical context that is no longer favorable to our study. This has… | Other (stated, no rule matched) |
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | — | withdrawn | Dec 9, 2019 | University Hospital, Grenoble | the possibility of obtaining histological data is too low due to the lack of availability of… | Other (stated, no rule matched) |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced… | Phase 1 | terminated | Feb 23, 2017 | SignalRX Pharmaceuticals, Inc. | Lack of recruitment and sponsor's priority changes | Enrollment / accrual |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Apollomics (Australia) Pty. Ltd. | Study terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04… | Phase 3 | withdrawn | Jul 10, 2020 | Shanghai Henlius Biotech | The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been… | Other (stated, no rule matched) |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | N/A | terminated | Mar 9, 2016 | Wake Forest University Health Sciences | Lack of funding | Funding |
| NCT04231929 | BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre…(BIOPEARL-FIRST) | N/A | withdrawn | Jan 18, 2020 | Terumo Europe N.V. | Study cancelled by Sponsor decision | Sponsor / business decision |
| NCT03979547 | EXALT: EXercise Attenuates Liver Tumors Trial(EXALT) | N/A | terminated | Jun 7, 2019 | Milton S. Hershey Medical Center | Recruitment challenges | Enrollment / accrual |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | Phase 1 | suspended | Aug 10, 2020 | Beijing Tsinghua Chang Gung Hospital | Adjust the plan | Other (stated, no rule matched) |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | Phase 2 | withdrawn | Apr 9, 2019 | Louisiana State University Health Sciences Center in New Orleans | Dr. Marshall left UMC and LSU Health Sciences Center. | Other (stated, no rule matched) |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | Phase 2 | terminated | Dec 4, 2020 | Zhejiang University | The treatment efficacy was not satisfactory. | Efficacy / futility |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | Phase 2 | terminated | Jul 20, 2020 | SC Liver Research Consortium, LLC | Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity… | Safety / toxicity |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of…(HiQuality) | Phase 3 | terminated | Jul 6, 2011 | Merit Medical Systems, Inc. | The clinical study was terminated due to the inability to meet target enrollment. | Enrollment / accrual |
| NCT03071094 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic… | Phase 1 / Phase 2 | terminated | Mar 6, 2017 | Transgene | The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab… | Other (stated, no rule matched) |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in…(DESPARTH) | Phase 1 | terminated | Dec 1, 2014 | University Hospital, Ghent | slow recruitment of patients | Enrollment / accrual |
| NCT01141478 | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San…(HCC) | N/A | terminated | Jun 10, 2010 | Loma Linda University | due to low enrollment | Enrollment / accrual |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | Phase 2 | withdrawn | Jul 1, 2021 | Shanghai Zhongshan Hospital | The standard of care of adjuvant therapy for liver cancer was changed. | Other (stated, no rule matched) |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | Phase 1 | terminated | Jun 29, 2017 | University of Chicago | Study stopped due to poor accrual. | Enrollment / accrual |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | Phase 2 | terminated | Dec 16, 2009 | New Mexico Cancer Research Alliance | Low accrual rate | Enrollment / accrual |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With… | Phase 2 | terminated | Aug 1, 2018 | Chang Gung Memorial Hospital | The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is… | Other (stated, no rule matched) |
| NCT04264754 | Characterization of Methylation Patterns in Hepatocellular Carcinoma | — | terminated | Feb 11, 2020 | Nucleix Ltd. | Sponsor prioritize other clinical projects over this study | Other (stated, no rule matched) |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the…(YES-P) | Phase 3 | terminated | Jun 27, 2013 | Boston Scientific Corporation | Poor Accrual. | Enrollment / accrual |
| NCT03452553 | Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With… | N/A | withdrawn | Mar 2, 2018 | Boston Scientific Corporation | CMS disapproval, no alternative for sites/patient, risk of financial burden. | Funding |
| NCT00892255 | Microwave Ablation of Resectable Liver Tumors | — | withdrawn | May 4, 2009 | St. Joseph Hospital of Orange | not stated | Not stated |
| NCT03563274 | QuiremSpheres Observational Study(Hope166) | — | terminated | Jun 20, 2018 | Terumo Europe N.V. | did not meet planned recruitment expectations with a slow recruitment rate | Enrollment / accrual |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | N/A | withdrawn | May 27, 2020 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | Low accrual rate | Enrollment / accrual |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For…(TheraBionics) | Phase 2 | withdrawn | Aug 25, 2020 | Wake Forest University Health Sciences | This application needs further attention in terms of FDA approval and will be reassigned under a… | Other (stated, no rule matched) |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo… | Phase 2 | terminated | Oct 6, 2017 | University of Alabama at Birmingham | study was terminated due to poor enrollment | Enrollment / accrual |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | Phase 2 | withdrawn | May 2, 2014 | Zhejiang University | patients not enrolled | Enrollment / accrual |
| NCT02460991 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(SOLACE) | Phase 3 | terminated | Jun 3, 2015 | Boston Scientific Corporation | Slow enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 14, 2022source: clinicaltrials